our Premium Content: News alerts, weekly reports and conference planners

GENE:

NEUROD1 (Neuronal Differentiation 1)

News alerts, weekly reports and conference planners

Ferroptosis as a Translational Axis in Small Cell Lung Cancer: A Systematic Review of Redox Pathways and Precision Oncology Prospects. (PubMed, Oncol Res)

Ferroptosis constitutes a promising therapeutic axis in SCLC. Integrating ferroptosis biomarkers into molecular stratification frameworks could refine patient selection and support precision oncology strategies, warranting further translational and clinical validation.

9 days ago

Review • Journal

CD8 (cluster of differentiation 8) • YAP1 (Yes associated protein 1) • STING (stimulator of interferon response cGAMP interactor 1) • GPX4 (Glutathione Peroxidase 4) • ACSL4 (Acyl-CoA Synthetase Long Chain Family Member 4) • POU2F3 (POU Class 2 Homeobox 3) • SLC7A11 (Solute Carrier Family 7 Member 11) • AIFM2 (Apoptosis Inducing Factor Mitochondria Associated 2) • ASCL1 (Achaete-Scute Family BHLH Transcription Factor 1) • NEUROD1 (Neuronal Differentiation 1)

11d

MYCN Gene Is Activated by High-Level Expression of Stress-Inducible Isoform of Oct-1 Transcription Factor in Human Neuroblastoma Cells. (PubMed, Dokl Biol Sci)

High-level expression of Oct-1Z increased expression of MYCN and its target gene NEUROD1. Oct-1Z was thus identified as an activator of MYCN expression and a potential target for neuroblastoma therapy in patients with high levels of MYCN.

11 days ago

Journal

MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • NEUROD1 (Neuronal Differentiation 1)

MYCN expression

16d

Molecular subtyping of small-cell lung cancer in clinical practice: Primary tumor-lymph node concordance, intratumoral heterogeneity, and genomic context in a Chinese cohort. (PubMed, Lung Cancer)

The observed discordance during regional nodal dissemination suggests that single site-dependent immunohistochemistry-based subtyping may be insufficient. Future frameworks incorporating multi-region analysis and liquid biopsy are essential to capture the dynamic evolution of SCLC and optimize personalized management for localized disease.

16 days ago

Journal

TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • RB1 (RB Transcriptional Corepressor 1) • NOTCH1 (Notch 1) • KMT2D (Lysine Methyltransferase 2D) • SLFN11 (Schlafen Family Member 11) • CREBBP (CREB binding protein) • YAP1 (Yes associated protein 1) • NFIB (Nuclear Factor I B) • POU2F3 (POU Class 2 Homeobox 3) • ASCL1 (Achaete-Scute Family BHLH Transcription Factor 1) • CASP10 (Caspase 10) • INSM1 (INSM Transcriptional Repressor 1) • NEUROD1 (Neuronal Differentiation 1)

23d

Orthogonal disentanglement of single-cell multi-omics reveals private and shared drivers of tissue development and pathogenesis. (PubMed, Proc Natl Acad Sci U S A)

In mouse secondary palate development, OmiDos precisely identified a cell type-specific unlinked distal enhancer, elucidating its essential role in the regulation of epithelial cell differentiation and migration. The application of OmiDos to medulloblastoma revealed a potential role deficiency in driving partial closure of the distal enhancer region of Neurod1 may contribute to the progression of medulloblastoma from normal to tumor states.

23 days ago

Journal

NEUROD1 (Neuronal Differentiation 1)

25d

Multi-omics reveals key molecular and cellular features of advanced small cell lung cancers associated with distinct therapeutic opportunities. (PubMed, Genome Med)

We showed that methylation of the most common source of tumor tissue in the clinical setting can stratify SCLCs with distinct clinical outcomes and potentially tailored therapeutic options. Methylation can characterize the intrinsic and extrinsic heterogeneity of SCLCs and fuel the discovery of novel therapeutic vulnerabilities to help bridge the gap between research and clinical application to improve care for SCLC patients.

25 days ago

Journal

CD8 (cluster of differentiation 8) • SLFN11 (Schlafen Family Member 11) • DLL3 (Delta Like Canonical Notch Ligand 3) • YAP1 (Yes associated protein 1) • POU2F3 (POU Class 2 Homeobox 3) • SEZ6 (Seizure Related 6 Homolog) • ASCL1 (Achaete-Scute Family BHLH Transcription Factor 1) • NEUROD1 (Neuronal Differentiation 1) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)

30d

Maternal obesity induces activator protein 1-mediated inflammatory response to impair embryonic neurogenesis. (PubMed, J Physiol)

MO elevates activator protein 1 (AP-1) transcription factor accessibility to the promoters of inflammatory genes. Inflammation induced by tumour necrosis factor-α (TNF-α) suppresses Neurod1 and Neurog2 expression and neurogenesis in vitro.

30 days ago

Journal

CD68 (CD68 Molecule) • ASCL1 (Achaete-Scute Family BHLH Transcription Factor 1) • NEUROD1 (Neuronal Differentiation 1) • NEUROG2( Neurogenin 2)

Cytologic Features Across Molecular Subtypes of Small Cell Lung Carcinoma: Classical Uniformity With Exceptions in POU2F3-Positive Cases. (PubMed, Cytopathology)

Cytomorphology is largely conserved across molecular subtypes of SCLC, but a minority of POU2F3-positive tumours may display non-classical features. Recognition of this variant is important to avoid misclassification, particularly when only limited cytology material is available. These findings suggest that lineage-defining programs may occasionally imprint the cytologic phenotype and highlight the value of considering subtype-oriented ancillary testing in challenging cases.

1 month ago

Journal

POU2F3 (POU Class 2 Homeobox 3) • ASCL1 (Achaete-Scute Family BHLH Transcription Factor 1) • NEUROD1 (Neuronal Differentiation 1)

Potential Immune Microenvironment Biomarkers in SCLC: J-TAIL-2 Observational Study. (PubMed, JTO Clin Res Rep)

Effective predictors of response to atezolizumab plus carboplatin/etoposide (CE) therapy in extensive-stage SCLC (ES-SCLC) remain limited. mOS and mPFS were not significantly different between SCLC subtypes but were numerically shorter in the SCLC-N group. CD8+ TIL density is a potential biomarker of clinical benefit in ES-SCLC and may facilitate patient selection for atezolizumab combination therapy.

1 month ago

Observational data • Journal • PD(L)-1 Biomarker

CD8 (cluster of differentiation 8) • POU2F3 (POU Class 2 Homeobox 3) • ASCL1 (Achaete-Scute Family BHLH Transcription Factor 1) • NEUROD1 (Neuronal Differentiation 1)

Tecentriq (atezolizumab) • carboplatin • etoposide IV

Multiomic characterization of small cell lung cancer: Real-world insights into therapeutic opportunities. (PubMed, Cancer)

This large-scale multiomic analysis revealed significant associations between SCLC subtypes and specific immune signatures and comutations. These findings provide insights into the molecular heterogeneity of SCLC, and highlight potential biomarkers for targeted therapies.

1 month ago

Journal • Real-world evidence • IO biomarker

BCL2 (B-cell CLL/lymphoma 2) • DLL3 (Delta Like Canonical Notch Ligand 3) • YAP1 (Yes associated protein 1) • STING (stimulator of interferon response cGAMP interactor 1) • SSTR2 (Somatostatin Receptor 2) • POU2F3 (POU Class 2 Homeobox 3) • SEZ6 (Seizure Related 6 Homolog) • ASCL1 (Achaete-Scute Family BHLH Transcription Factor 1) • NEUROD1 (Neuronal Differentiation 1)

MI Tumor Seek™

2ms

Immunohistochemical profiling of small cell lung cancer reveals subtype heterogeneity and a tuft cell-like subtype characterized by LRMP and TRPM5. (PubMed, Virchows Arch)

SCLC exhibits molecular heterogeneity, with ASCL1- and NEUROD1-driven tumors representing the most frequent subtypes. A distinct subset of ASCL1/NEUROD1 double-negative tumors showed high POU2F3 expression together with LRMP and TRPM5, supporting a tuft cell-like subtype and refining the immunohistochemical characterization of this rare SCLC subset.

2 months ago

Journal

YAP1 (Yes associated protein 1) • POU2F3 (POU Class 2 Homeobox 3) • ASCL1 (Achaete-Scute Family BHLH Transcription Factor 1) • NEUROD1 (Neuronal Differentiation 1) • ASCL2 (Achaete-Scute Family BHLH Transcription Factor 2)

2ms

Subclassification of Small Cell Lung Cancer Based on Gene Expression Signatures and Machine Learning. (PubMed, Cancer Res Commun)

We propose a diagnostic algorithm for NAPY classification which demands that high expression of a NAPY TFs is matched by a high signal of its downstream expression signature, thereby providing functional robustness to NAPY class calls compared to schemes that rely solely on the expression of TFs. Based on this NAPY consensus classification of our SCLCs we describe the redetection of known and identification of novel associations of molecular and clinical patters across the four major molecular subtypes.

2 months ago

Journal

YAP1 (Yes associated protein 1) • POU2F3 (POU Class 2 Homeobox 3) • ASCL1 (Achaete-Scute Family BHLH Transcription Factor 1) • NEUROD1 (Neuronal Differentiation 1)

2ms

Vestigial-like 4 Regulates Neurogenesis and Neural Crest Formation During Xenopus Development. (PubMed, J Dev Biol)

Collectively, our findings demonstrate that vestigial-like 4 is an important regulator of neurogenesis and neural crest formation. Although vestigial-like 4 can bind to tead proteins in the embryo, its function does not depend solely on this interaction, suggesting a complex level of regulation with which vestigial-like 4 regulates early steps in development and differentiation.

2 months ago

Journal

SOX9 (SRY-Box Transcription Factor 9) • NEUROD1 (Neuronal Differentiation 1) • NEUROG1 (Neurogenin 1) • PAX3 (Paired Box 3)